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S U M M A R Y
Objectives: The objectives of this studywere to compare the performance of the LightCycler SeptiFast Test
MGRADE and conventional blood culture in the etiological diagnosis of febrile episodes occurring in
neutropenic and critically ill patients (in the intensive care unit; ICU), and to assess the potential clinical
value of the SeptiFast test in patient management.
Methods: A total of 86 febrile episodes occurring in 33 neutropenic patients and 53 ICU patients were
analyzed. Blood samples for blood culture and SeptiFast testingwere obtained at the onset of fever, before
the implementation of empirical antimicrobial therapy.
Results: The overall microorganism-to-isolate agreement between the SeptiFast test and blood culture
was 69% (k = 0.37) in neutropenic patients and 75% (k = 0.56) in ICU patients. The sensitivity of the
SeptiFast assay for clinically relevant episodes of bacteremia and fungemia was 62% in neutropenic
patients and 70% in ICU patients. Based on SeptiFast results, empirical treatments were deemed adequate
in all but one of the febrile episodes. Nevertheless, early antibiotic treatment readjustment was judged
feasible in most of clinically signiﬁcant episodes overall.
Conclusions: The SeptiFast assay is a valuable ancillary method for the diagnosis of bloodstream
infections in neutropenic and ICU patients. In these clinical settings, results of the SeptiFast assay may
lead to a more targeted antibiotic therapy early after the onset of fever.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Bloodstream infections are associated with signiﬁcant morbid-
ity andmortality in both neutropenic and critically ill patients.1,2 A
favorable clinical outcome is directly related to rapid etiological
diagnosis and prompt administration of effective antimicrobial
therapy.3,4 Early therapeutic management of febrile episodes in
these patients includes the empirical administration of broad-
spectrum antimicrobial agents, since the results of blood cultures,
currently the gold standardmethod for the detection of bacteremia
and fungemia, are not available until 48–72 h after sample
collection.5 Reassessment of antimicrobial therapy upon receipt
of blood culture results is then recommended, as a more targeted* Corresponding author. Tel.: +34 96 3864657; fax: +34 96 3864173.
E-mail address: david.navarro@uv.es (D. Navarro).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.01.003antimicrobial regimen minimizes toxicity, reduces costs, and
lowers the probability of the emergence of microbial resistance.
Conventional blood culture methods have several drawbacks,
such as the possibility of providing false-positive results due to
contamination and false-negative results due to their relative
insensitivity, particularly in patients on antimicrobial therapy at
the time of sampling.5 In this sense, it has been shown that only
30% of blood cultures obtained at the onset of fever are positive in
febrile neutropenic patients.2,6
PCR-based methods detecting microbial DNA directly in blood
specimens are a promising approach for the rapid diagnosis of
bacteremia and fungemia.7 Among these, the LightCycler1
SeptiFast Test, a commercially available multiplex real-time PCR
assay able to detect up to 25 bacterial and fungal organisms
commonly involved in systemic infections, has recently been the
focus of much attention. The performance of the SeptiFast test has
been evaluated in different clinical settings.8–20 Overall, theses. Published by Elsevier Ltd. All rights reserved.
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that of blood culture. Nevertheless, further studies are needed in
order to determine whether the information provided by the
SeptiFast test leads to the improved therapeutic management of
patients with suspected bloodstream infections.
In the present studywe evaluated the diagnostic accuracy of the
SeptiFast test in comparison with that of conventional blood
culture in the etiological diagnosis of febrile episodes occurring in
neutropenic and critically ill patients. We also retrospectively
assessed the potential utility of the information provided by the
SeptiFast assay in the therapeutic management of these patients
early after the onset of fever.
2. Materials and methods
2.1. Patients
This was an observational study conducted in the Hematology
Unit and the Medical and Surgical ICU of the Hospital Clı´nico
Universitario, Valencia (Spain) over a 8-month period. The
inclusion criterion used was the development of a febrile episode
that required hospital admission or occurred during hospital stay.
The exclusion criterion was the receipt of empirical antibiotic
treatment prior to blood sampling for analysis. Patients who met
the inclusion criterion and who were under the care of the
physicians listed among the authors of this manuscript were
recruited into the study. The study was conducted following local
ethics rules.
A total of 86 non-consecutive patients were enrolled between
February and September 2009. The Hematology Unit cohort
consisted of 33 patients (median age 58 years, range 24–80 years;
18males and 15 females). The underlying clinical conditions of the
patients were as follows: hematological malignancy under
chemotherapy (n = 18), allogeneic stem cell transplantation
(n = 10), and autologous stem cell transplantation (n = 5). Patients
in the Hematology Unit presented with febrile (axillary tempera-
ture > 38.0 8C) neutropenia (<0.5  109 neutrophils/l) either of
unknown origin or related to peripheral or central venous catheter
implantation. Blood samples were drawn at the onset of fever for
blood culture (two sets, following local guidelines) and SeptiFast
testing. Patients were on antibacterial (ﬂuoroquinolones; except
for autologous transplant patients) and antifungal (posaconazole)
prophylaxis at the time of sampling, and were treated empirically
after blood collection with either ceftazidime plus amikacin or
meropenem at conventional doses upon the appearance of fever.
Vancomycin was later added if Gram-positive cocci were observed
on direct smears from two positive blood cultures, or from one
positive blood culture if eithermucositis grade2was present or a
catheter-related bacteremia was suspected (presence of phlebitis
or signs of inﬂammation at the insertion site).
A total of 53 patients were included in the ICU cohort (median
age 65.5 years, range 23–86 years; 33 males and 20 females).
Patients were admitted to the ICU after heart surgery (n = 8),
neurosurgery or cerebrovascular accident (n = 11), or due to acute
respiratory failure (n = 11), severe sepsis or septic shock of
pulmonary, urinary or soft tissue origin (n = 15), drug intoxication
(n = 3), or other causes (n = 5). Patients in the ICU either presented
with fever or developed fever during their ICU stay. Blood samples
for blood cultures (three sets) and SeptiFast testing were obtained
at the onset of fever, before the implementation of empirical
antimicrobial therapy. Febrile episodes in these patients were
therapeutically managed at the physician’s discretion on the basis
of the suspected etiology, local microorganism resistance patterns,
the severity of illness, and the nature of prior antibiotic treatments.
Antimicrobial therapy administered to patients is described when
deemed appropriate.2.2. Microbiological studies
Blood was drawn by sterile venous puncture and processed
using the automated continuous monitoring blood culture system
Bactec 9420 BC (Becton Dickinson, Heidelberg, Germany). Each set
of blood cultures consisted of a pair of bottles for aerobic and
anaerobic bacteria and an additional bottle for fungal recovery. The
blood cultures were incubated for a maximum of 7 days. Each
bottle was inoculated with 10 ml of blood. The different sets of
blood cultures were obtained at intervals of 30 min. Direct smear
examination (Gram staining) was performed from positive blood
cultures as soon as detected, the clinicians being immediately
notiﬁed of the results by telephone. This usually occurred >16 h
after blood culture incubation. Direct antimicrobial susceptibility
testing was then performed by the disk diffusion method. Isolated
microorganisms were identiﬁed by standard methods and criteria.
Ethylenediaminetetraacetic acid (EDTA)-whole blood was
simultaneously obtained from patients for the detection of
microbial DNA using the LightCycler SeptiFast Test MGRADE
(Roche Diagnostics GmbH, Manheim, Germany), as recommended
by themanufacturer. Total DNAwas extracted from1.5 ml of blood
by means of the SeptiFast Lys Kit on the MagNA Lyser instrument
(Roche Diagnostics). Real-time detection of PCR products was
performed using the LightCycler 2.0 instrument (Roche Diagnos-
tics). A full description of the procedure, as well as the target
microbial species of the SeptiFast test, have previously been
reported.8,14 PCR testing was performed retrospectively on speci-
mens that had been stored at 20 8C so that results had no
inﬂuence on antimicrobial therapy. A single blood sample per
febrile episode was obtained for SeptiFast testing.
Microbiological cultures of samples from other sites (lower
respiratory tract specimens, urine, or catheter tips) were per-
formed when clinically indicated. Ventilator-associated pneumo-
nia was diagnosed following previously published criteria.21
Personnel performing the SeptiFast assay were blinded to the
results of the blood culture.
2.3. Deﬁnitions and interpretation of the data
Signiﬁcant bacteremia or fungemia was deﬁned by microbial
growth in one or more blood culture sets. For typical microbial
contaminants, such as coagulase-negative Staphylococcus species
(CoNS), Streptococcus spp, Corynebacterium spp, or Bacillus spp, the
isolation of the same bacterial species with an identical
antimicrobial susceptibility proﬁle in at least two blood cultures
from different blood samplings was required. In patients attending
the Hematology Unit, bacterial isolation in one blood culture
coupled with the isolation of the same species with an identical
antimicrobial susceptibility pattern on a semiquantitative catheter
tip culture was also considered to represent a signiﬁcant
bacteremia. In this clinical setting, the signiﬁcance of either the
isolation of a potentially contaminating microorganism in a single
set of blood cultures or the detection of CoNS DNA in blood by the
SeptiFast assay was judged on the basis of clinical grounds.
Discordant results between the assays were resolved on the basis
of available clinical (i.e., response to therapy) and microbiological
(cultures from other sites) data.
The sensitivity (true positives/(true positives + false negatives))
of the SeptiFast assay was calculated taking only relevant isolates
(non-contaminant) into consideration. We used simple Kappa
statistics to measure the degree of agreement between the assays
using SPSS v. 15.0 (SPSS Inc., Chicago, IL, USA).
A retrospective analysis of the test results and clinical data was
performed in order to assess the adequacy of empirical therapeutic
regimens administered to patients and to determine whether the
information provided by the SeptiFast assay would have had any
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deemed adequate when it provided cover for the causal
microorganism and the pathogen was found to be susceptible to
at least one of the antimicrobials used. The appropriateness of
adjustment or de-escalation of empirical antimicrobial therapy on
the basis of the SeptiFast results was assessed taking into
consideration the local antimicrobial susceptibility proﬁles of
the detected microorganisms. Appropriate streamlining of empir-
ical antimicrobial therapy included the following potential
adjustments: (1) suppression of one out of two broad-spectrum
antibiotics providing cover for the causal microorganisms (i.e.,
meropenem or levoﬂoxacin for Enterobacteriaceae), (2) suppres-
sion of an antibiotic with activity against beta-lactam-resistant
Gram-positive cocci (vancomycin, linezolid, or daptomycin) when
Gram-negative bacterial DNA was detected, and (3) suppression of
broad-spectrum antibiotics (i.e., meropenem)whenGram-positive
cocci were detected, provided that an antibiotic with activity
against beta-lactam-resistant Gram-positive cocci (vancomycin,
linezolid, or daptomycin) was included in the therapeutic regimen.
The appropriateness and feasibility of antibiotic adjustments were
judged independently by two of the authors.
3. Results
3.1. Performance of the SeptiFast assay in febrile neutropenic patients
Blood samples from 33 febrile neutropenic patients were
examined. All but three febrile episodes resolved within the study
period.Data regarding themicroorganismsdetectedby theSeptiFast
assay and recovered by blood culture are summarized in Table 1.
Twenty-ﬁve episodes were associated with a positive blood
culture. A single microorganism was isolated in all cases. Out of
these 25 episodes, nine had a positive result by the SeptiFast test,
which was concordant with that of the blood culture in six cases
(CoNS n = 3, Streptococcus spp, Klebsiella pneumoniae/oxytoca, and
Serratia marcescens) and discordant in the remaining three cases.
Microbiological ﬁndings in the latter cases were as follows: in one
case Stenotrophomonas maltophilia was detected by the SeptiFast
assay, while CoNS (contaminant) was isolated from the blood
culture; in another episode, Acinetobacter baumannii and Escher-
ichia coli were detected by the SeptiFast assay, but only the latter
was recovered from the blood culture. The presence of S.
maltophilia DNA in blood was deemed clinically meaningless as
the febrile episode resolvedwith an antibiotic regimen that did not
provide cover for the microorganism (meropenem). The clinical
relevance of A. baumannii DNA detection by the SeptiFast assay
could not be ascertained. In the remaining case, Enterococcus
faecium was isolated from the blood culture and Staphylococcus
aureus was detected by the SeptiFast assay.Table 1
Microorganisms detected by the SeptiFast assay and recovered by blood culture in feb













a Eight coagulase-negative staphylococci detected only by blood culture and two de
b Not included in the SeptiFast master list.Sixteen blood culture-positive episodes had a negative Septi-
Fast result. Of these, 12 yielded CoNS, which were interpreted as
contaminants in eight cases. In two cases microorganisms not
included in the SeptiFast panel list were isolated (Corynebacterium
spp and Bacillus spp). In the remaining two cases E. coliwas missed
by the SeptiFast assay.
No blood culture-negative samples tested positive by the
SeptiFast assay, and bothmethods yielded negative results in eight
episodes. The overall microorganism-to-isolate agreement (nega-
tive results in both assays and positive results in both assays
yielding the same microbial species) between the assays was 48%,
but increased to 69% (k = 0.37) if specimens yielding CoNS judged
as contaminants and microorganisms not included in the SeptiFast
panel list were excluded from the analysis. The sensitivity for
clinically relevant microorganisms of the SeptiFast assay was 62%
and of blood culture was 74%.
3.2. Potential therapeutic relevance of the information provided by
the SeptiFast assay in febrile neutropenic patients
Retrospective analysis of the clinical and microbiological data
for episodes in which both the SeptiFast assay and the blood
culture tested positive indicated the following (Table 2): (1) the
empirical treatment was deemed adequate in six out of the seven
clinically relevant febrile episodes; in the remaining case the result
provided by the SeptiFast assay would have recommended a
change in the empirical antibiotic regimen because of the lack of
cover for the detected microorganism (S. maltophilia), even though
the clinical signiﬁcance of this ﬁnding was later dismissed; (2)
adjustment of empirical therapy on the basis of the SeptiFast
results would have been considered appropriate in the above-
mentioned case (S. maltophilia) and in an additional three febrile
episodes due to S. aureus, Streptococcus mitis and CoNS, respec-
tively, in which either meropenem or the combination of
ceftazidime/amikacin could have been suspended; (3) implemen-
tation of vancomycin on the basis of Gram stain results would have
been avoided in six patients in whom clinically irrelevant CoNS
were isolated had the result of the SeptiFast assay (negative) been
taken into consideration; (4) the SeptiFast assay missed four
clinically relevant CoNS; (v) results of the SeptiFast assay would
have led to the inappropriate addition of vancomycin to the
empirical antibiotic regimen in two febrile episodes (CoNS
detected were interpreted as clinically irrelevant).
3.3. Performance of the SeptiFast assay in febrile episodes in the ICU
patients
Blood samples from 53 febrile episodes were examined. All but
seven episodes resolved within the study period. Data regardingrile episodes occurring in neutropenic patients
th a positive result by:












tected by both methods were judged to be contaminants.
Table 3
Microorganisms detected by the SeptiFast assay and recovered from blood culture in febrile episodes occurring in ICU patients
Species Number of samples with positive result by:
Blood culture only SeptiFast assay only Both assays
Coagulase-negative staphylococcia 9 1 1
Staphylococcus aureus 2 0 2
Enterococcus faecalis 0 0 1
Streptococcus sppb 0 1 0
Escherichia coli 1 1 1
Serratia marcescens 0 0 1
Klebsiella pneumoniae/oxytoca 0 0 1
Enterobacter cloacae/aerogenes 1 1 1
Pseudomonas aeruginosa 0 1 1
Candida albicans 0 0 1
Aspergillus sppc 0 1 0
ICU, intensive care unit.
a Seven out of the 11 coagulase-negative staphylococci were considered contaminants.
b Interpreted as a contaminant.
c The detection of Aspergillus spp DNA was judged clinically irrelevant based on microbiological and clinical data.
Table 2
Potential therapeutic relevance of the information provided by the SeptiFast assay in febrile neutropenic patients with clinically signiﬁcantmicroorganisms isolated by blood
culture
Microorganism detected
by SF / BC result
Probable origin
of infection
Empirical treatment and its adequacy.a Feasibility of antibiotic adjustment
Serratia marcescens / identical Unknown Meropenem. Adequate. Adjustment not feasible
Klebsiella pneumoniae/oxytoca / Klebsiella
pneumoniae
Unknown Meropenem. Adequate. Adjustment not feasible
Stenotrophomonas maltophilia / CoNS Unknown Meropenem. Inadequate.b Adjustment feasible:
addition of trimethoprim–sulfamethoxazole
Escherichia coli + Acinetobacter baumannii / Escherichia coli Unknown Meropenem. Adequate. Adjustment not feasible
Staphylococcus aureus / Enterococcus faecium Unknown Meropenem. Vancomycin was added on the basis
of Gram stain results. Adequate. Adjustment feasible: suppression of meropenem
Streptococcus spp / Streptococcus mitis Unknown Ceftazidime/amikacin. Vancomycin was added on the basis
of Gram stain results. Adequate. Adjustment feasible: suppression
of broad-spectrum antibiotics
CoNS / identicalc Catheterd Ceftazidime/amikacin. Vancomycin was added on the basis of
Gram stain results. Adequate. Adjustment feasible: suppression
of broad-spectrum antibiotics
SF, SeptiFast assay; BC, blood culture; CoNS, coagulase-negative staphylococci.
a An empirical therapeutic regimen was deemed adequate when providing coverage for the causal microorganism.
b Even though Stenotrophomonasmaltophiliawas eventually judged as clinically irrelevant, addition of antimicrobials speciﬁcally targeting thismicroorganismwould have
been considered adequate within that time frame.
c Two out of the three CoNS detected by the SeptiFast assay and recovered from blood culture were interpreted as contaminants.
d CoNS (Staphylococcus epidermidis) with an identical antimicrobial susceptibility proﬁle were isolated from blood and from the semiquantitative catheter tip culture.
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by blood culture are summarized in Table 3.
Twenty-ﬁve episodes were associated with a positive blood
culture. A single microorganism was isolated in all cases. Of these,
12 had a positive result by the SeptiFast test and 13 had a negative
SeptiFast result. In the former episodes, concordant results were
obtained in 10 cases and discordant results in two cases (CoNS in
blood culture and E. coli by the SeptiFast assay, and CoNS in blood
culture and Aspergillus spp by the SeptiFast assay). The detection of
Aspergillus spp DNA by the SeptiFast assay was considered as a
false-positive result on the basis of analytical galactomannan-
negative results on serum and clinical grounds. In the latter
episodes, the following microorganisms were recovered from
blood culture: CoNS (n = 9), six of which were considered as
contaminants, methicillin-susceptible S. aureus (MSSA), methicil-
lin-resistant S. aureus (MRSA), E. coli, and Enterobacter cloacae. Four
episodes with a negative blood culture result tested positive by the
SeptiFast assay. The microorganisms detected in these episodes
were E. cloacae/aerogenes, Pseudomonas aeruginosa, CoNS and
Streptococcus spp. The latter two were considered contaminants
based on clinical grounds. P. aeruginosawas later recovered from a
second set of blood cultures (not shown). A negative result in both
tests was obtained in 24 febrile episodes. The overall microorgan-
ism-to-isolate agreement between the two assays was 64%, butincreased to 75% (k = 0.56) when the clinically irrelevant micro-
organisms recovered from blood culture or detected by the
SeptiFast assaywere excluded from the analysis. In this setting, the
sensitivity of the SeptiFast assay was 70% and of blood culture was
73%.
3.4. Potential therapeutic relevance of the information provided by
the SeptiFast assay in febrile patients in the ICU
As shown in Table 4, empirical treatments administered to
febrile ICU patients with clinically relevant positive results by the
SeptiFast assay alone or by the SeptiFast assay and blood culture
were deemed adequate in all cases. Nevertheless, antibiotic
adjustments consisting of: (1) suppression of either broad-
spectrum antibiotics (meropenem, levoﬂoxacin, or the combina-
tion ceftazidime/amikacin) or antibiotics targeting beta-lactam-
resistant Gram-positive bacteria (linezolid or daptomycin), (2)
addition of the latter type of antimicrobials, and (3) substitution of
broad-spectrum antibiotics (levoﬂoxacin or cefepime) by carba-
penems (on the basis of the antibiotic resistance proﬁle of the
circulating microorganisms, quinolone-resistant and extended-
spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae)
were considered potentially feasible in all but three episodes; in
two out of the latter episodes, P. aeruginosa was detected and the
Table 4
Potential therapeutic relevance of the information provided by the SeptiFast assay in febrile patients in the ICU with clinically signiﬁcant positive results obtained either by
the SeptiFast assay alone or by the SeptiFast assay and blood culture
Microorganism detected
by SF assay / BC results
Probable origin
of infectiona
Empirical treatment and its adequacy.b Feasibility of antibiotic adjustment
Enterococcus faecalis / identical Urinary tract Ceftazidime/gentamicin/vancomycin. Adequate. Adjustment feasible:
suppression of broad-spectrum
antibiotic therapy
Staphylococcus aureus / MSSA Unknown Meropenem/levoﬂoxacin. Adequate. Adjustment feasible: addition
of vancomycin/linezolid/daptomycin and suppression of broad-spectrum antibiotic therapy
Staphylococcus aureus / MRSA Catheter Meropenem. Linezolid added on the basis of Gram stain results. Adequate. Adjustment feasible:
suppression of meropenem
Enterobacter cloacae / negative Respiratoryc Meropenem/linezolid. Adequate. Adjustment feasible: suppression of linezolid
Pseudomonas aeruginosa / negative Respiratoryc Meropenem/levoﬂoxacin. Adequate. Adjustment not feasible
Serratia marcescens / identical Respiratoryc Levoﬂoxacin/linezolid. Adequate. Adjustment feasible: addition of a carbapenem
agent and suppression of linezolid
Escherichia coli / CoNSd Respiratoryc Cefepime. Linezolid added on the basis of Gram stain results. Adequate. Adjustment
suitable: carbapenem therapy instead of cefepime and suppression of linezolid
Escherichia coli / identical Unknown Levoﬂoxacin/daptomycin. Adequate. Adjustment feasible: carbapenem therapy
instead of levoﬂoxacin and suppression of linezolid
Enterobacter cloacae/aerogenes / Enterobacter
cloacae
Respiratoryc Meropenem. Adequate. No adjustment feasible
Pseudomonas aeruginosa / identical Respiratoryc Meropenem/levoﬂoxacin. Adequate. No adjustment feasible
Klebsiella pneumoniae/oxytoca / Klebsiella
pneumoniae
Urinary Meropenem/levoﬂoxacin. Adequate. Adjustment
feasible: suppression of levoﬂoxacin
Candida albicans / identical Catheter Levoﬂoxacin. Caspofungin added on the basis of Gram stain. Adequate. Adjustment feasible:
suppression of levoﬂoxacin
CoNS / CoNS Catheter Meropenem. Linezolid added on the basis of Gram stain. Adequate.
Adjustment feasible: suppression of meropenem
ICU, intensive care unit; SF, SeptiFast assay; BC, blood culture; CoNS, coagulase-negative staphylococci; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA,
methicillin-resistant Staphylococcus aureus.
a The same bacterial species was recovered from the indicated source.
b An empirical therapeutic regimen was deemed adequate when providing cover for the causal microorganism.
c Ventilator-associated pneumonia.
d CoNS considered as a contaminant.
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adjustable (due to circulating strains resistant to either quinolones
or carbapenems, or both). E. cloacae/aerogeneswas detected by the
SeptiFast assay in the remaining episode. In this case, the
meropenem therapy was judged not to be adjustable, as
derepressed AmpC beta-lactamase-producing Enterobacter spp
strains have been shown to circulate in this setting.
4. Discussion
The primary objective of the current study was to compare the
performance of the SeptiFast assay with that of conventional blood
culture in the etiological diagnosis of suspected bloodstream
infections occurring in neutropenic (under antibiotic prophylaxis)
and critically ill (antibiotic-naı¨ve) patients presenting with fever,
with or without focal signs of infection. We were particularly
interested in assessing the analytical performance of bothmethods
at the precise moment of the onset of fever, when decisions
regarding the antibiotic regimen to be implemented have the
greatest impact on the clinical outcome. Thus, samples drawn only
once from any given patient were considered for analysis. Overall,
we found that the blood culture was more sensitive than the
SeptiFast assay. This was mostly due to the great number of CoNS
deemed to be clinically irrelevant that were recovered from blood
culture but not detected by the SeptiFast assay. This was not
unexpected, as the SeptiFast assay has been designed to avoid the
detection of CoNS DNA present at low concentrations (contami-
nating bacteria).8 In fact, when clinically irrelevant microorgan-
isms isolated from blood culture were excluded from the analysis,
both assays were found to display comparable sensitivities.
The fact that neutropenia minimizes the likelihood of detecting
microbial DNA in blood may have been responsible for the
relatively low diagnostic yield of the SeptiFast assay in our
hematology patients.16 Previously published data on the sensitivi-ty of the SeptiFast assay in comparison with that of blood culture
are rather heterogeneous. In some studies, the SeptiFast assay has
been found to be clearly superior,9–11,17–19 whereas in others both
methods have either displayed similar sensitivities or the SeptiFast
assay has compared unfavorably with respect to blood cul-
ture.15,16,20 Differences in the characteristics and clinical condi-
tions of patients (rather heterogeneous in our study), the spectrum
of microorganisms detected, the number of blood culture sets
drawn, the volume of blood drawn for culture, and the presence or
absence of ongoing antibiotic therapy at the time of sampling
among the studies may account for these discrepancies.
For clinically relevant microorganisms, the overall microorgan-
ism-to-isolate agreement between the SeptiFast and the blood
culture results was relatively modest (69% for patients in the
Hematology Unit and 75% for those in the ICU) and in line with
previously reported data.16,18,20 The SeptiFast assay failed to detect
several clinically signiﬁcant species, such as E. coli (n = 3), E.
cloacae, MSSA, and MRSA. The failure of the SeptiFast assay in
detecting the latter two species may be related to the fact that
bacterial lysis in this system is more difﬁcult for Gram-positive
bacteria.19 With respect to the former species, analogous data to
those reported herein have been published.15–18,20
The interpretation of the detection of bacterial or fungal DNA in
the absence of a positive blood culture is not straightforward, since
circulating DNA may come from non-viable microorganisms or
from microorganisms inhibited by antimicrobials. Furthermore,
microbial DNA detected by the SeptiFast assay may even come
from contaminant environmentalmicroorganisms. Our experience
on this matter is rather conﬂicting. On the one hand, the presence
of bacterial DNA in blood in two out of four febrile episodes
occurring in critically ill patients (P. aeruginosa and E. cloacae/
aerogenes) was deemed relevant on the basis of clinical ﬁndings
and microbiological data. On the other hand, the clinical
signiﬁcance of the detection of DNA from S. maltophilia, A.
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episodes could not be demonstrated. Thus, positive results
obtained by the SeptiFast assay in the absence of microbial
recovery by blood culture must be interpreted with caution; it is
our opinion, nonetheless, that they should be considered as
reﬂecting true infections unless proven otherwise.
A remarkable discrepancy between the results obtained by the
SeptiFast assay and those of blood culture was noted in an episode
of febrile neutropenia. In this case, E. faecium was recovered from
blood culture while S. aureus DNA was detected by the SeptiFast
assay. We are unaware of a previous publication reporting such an
analogous ﬁnding, for which we have no explanation.
Taken altogether, our study indicates that the SeptiFast assay
may complement but not substitute blood culture in the etiological
diagnosis of bloodstream infections.
The secondary objective of the present study was to assess
whether the information provided by the SeptiFast testwould have
had any impact on the early antibiotic management of febrile
episodes in these clinical settings had the results been available to
the clinician in a timely fashion (6–7 h after sample collection).We
judged the appropriateness of the empirical antibiotic regimens
administered to the patients and assessed whether adjustments to
narrow the antibiotic cover would have been feasible after
implementation of empirical antibiotic therapy. It is well known
that early de-escalation of broad-spectrum antibiotic treatment is
of paramount relevance for minimizing the risk of the emergence
of resistant microorganisms and for lowering costs. The major
limitation of our approachwas obviously its retrospective and non-
interventional nature, so that the clinical safeness of the suggested
antibiotic readjustments could not be demonstrated. Nevertheless,
our data suggest that the results of the SeptiFast assay may have
led to a more targeted antibiotic therapy, particularly in ICU
patients.
In particular, in the Hematology Unit patients, broad-spectrum
antimicrobial therapy (meropenem or the combination of cefta-
zidime/amikacin) could have been suspended early after the onset
of fever and substituted by an antibiotic with activity against beta-
lactam-resistant Gram-positive microorganisms in three out of
seven clinically relevant febrile episodes. We acknowledge,
however, that this interventional strategy is not universally
recommended in the antibiotic management of febrile episodes
in neutropenic patients, but in our opinion it deserves further
attention. Furthermore, the ability of the SeptiFast test to
discriminate between true infection and contamination due to
CoNS would have spared the addition of vancomycin (on the basis
of Gram stain results) to the empirical antibiotic regimen in six
patients in whom clinically irrelevant CoNS were isolated.
Likewise, readjustments of empirical antibiotic therapy based
on the SeptiFast results were deemed potentially feasible in most
clinically signiﬁcant febrile episodes occurring in the ICU patients.
These would have consisted of the suppression of either broad-
spectrum antibiotics or antibiotics targeting beta-lactam-resistant
Gram-positive bacteria, addition of the latter type of antibiotics, or
the substitution of broad-spectrum antibiotics such as levoﬂoxacin
or cefepime by carbapenems.
In summary, our data indicate that the SeptiFast assay is a
valuable ancillary method for the diagnosis of bloodstream
infections in neutropenic and critically ill patients. In these clinicalsettings, the results of the SeptiFast assay may lead to a more
targeted antibiotic therapy early after the onset of fever.
Nevertheless, interventional studies are needed to validate this
assumption.
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